DDInter1607 DDInter717
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome and Lennox-Gastaut syndrome through the restricted FINTEPLA REMS program. It is currently sold under the name FINTEPLA® by Zogenix INC.
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fenfluramine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Regorafenib
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Tolterodine
Tolterodine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fenfluramine
Ritonavir {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Ritonavir {u} (Compound) causes {v} (Side Effect) Visual impairment
Visual impairment {u} (Side Effect) is caused by {v} (Compound) Tolmetin
Tolmetin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Ritonavir {u} (Compound) causes {v} (Side Effect) Gastrooesophageal reflux disease
Gastrooesophageal reflux disease {u} (Side Effect) is caused by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Ritonavir {u} (Compound) causes {v} (Side Effect) Gastrooesophageal reflux disease
Gastrooesophageal reflux disease {u} (Side Effect) is caused by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Indomethacin (Compound) and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Fenfluramine
Ritonavir (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Regorafenib (Compound) and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Ritonavir (Compound) causes Visual impairment (Side Effect) and Visual impairment (Side Effect) is caused by Tolmetin (Compound) and Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Fluvoxamine (Compound) and Fluvoxamine may lead to a major life threatening interaction when taken with Fenfluramine
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may lead to a major life threatening interaction when taken with Fenfluramine
Ritonavir (Compound) causes Gastrooesophageal reflux disease (Side Effect) and Gastrooesophageal reflux disease (Side Effect) is caused by Fluvoxamine (Compound) and Fluvoxamine may lead to a major life threatening interaction when taken with Fenfluramine
Ritonavir (Compound) causes Gastrooesophageal reflux disease (Side Effect) and Gastrooesophageal reflux disease (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran may lead to a major life threatening interaction when taken with Fenfluramine